These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2818622)

  • 21. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
    Chua AC; Ingram HA; Raymond KN; Baker E
    Eur J Biochem; 2003 Apr; 270(8):1689-98. PubMed ID: 12694182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
    Richardson DR
    Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aluminum mobilization by desferrioxamine assessed by microdialysis of the blood, liver and brain.
    Yokel RA; Lidums V; Ungerstedt U
    Toxicology; 1991 Mar; 66(3):313-24. PubMed ID: 2011855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cellular iron concentration on iron uptake by hepatocytes.
    Trinder D; Batey RG; Morgan EH; Baker E
    Am J Physiol; 1990 Oct; 259(4 Pt 1):G611-7. PubMed ID: 2221071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron mobilization from isolated hepatocytes.
    Mostert LJ; de Jong G; Koster JF; van Eijk HG
    Int J Biochem; 1986; 18(11):1061-4. PubMed ID: 3803697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner.
    Watts RN; Richardson DR
    Eur J Biochem; 2002 Jul; 269(14):3383-92. PubMed ID: 12135476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcellular localization of ferritin and iron taken up by rat hepatocytes.
    Sibille JC; Ciriolo M; Kondo H; Crichton RR; Aisen P
    Biochem J; 1989 Sep; 262(2):685-8. PubMed ID: 2803277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships among desazadesferrithiocin analogues.
    Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Huang G
    Adv Exp Med Biol; 2002; 509():167-84. PubMed ID: 12572994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
    Florence A; Ward RJ; Peters TJ; Crichton RR
    Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of iron chelators on placental uptake and transfer of iron in rat.
    Wong CT; McArdle HJ; Morgan EH
    Am J Physiol; 1987 May; 252(5 Pt 1):C477-82. PubMed ID: 3578500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The desferrithiocin pharmacophore.
    Bergeron RJ; Liu CZ; McManis JS; Xia MX; Algee SE; Wiegand J
    J Med Chem; 1994 May; 37(10):1411-7. PubMed ID: 8182699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Uptake and intracellular metabolism of ferritin by primary cultured rat hepatocytes].
    Mikami T
    Nihon Ika Daigaku Zasshi; 1991 Jun; 58(3):317-28. PubMed ID: 1652594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
    Porter JB; Rafique R; Srichairatanakool S; Davis BA; Shah FT; Hair T; Evans P
    Ann N Y Acad Sci; 2005; 1054():155-68. PubMed ID: 16339661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
    Bergeron RJ; Wiegand J; Ratliff-Thompson K; Weimar WR
    Ann N Y Acad Sci; 1998 Jun; 850():202-16. PubMed ID: 9668541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative evaluation of iron clearance models.
    Bergeron RJ; Streiff RR; Wiegand J; Vinson JR; Luchetta G; Evans KM; Peter H; Jenny HB
    Ann N Y Acad Sci; 1990; 612():378-93. PubMed ID: 2127168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of desferrithiocin, an oral iron chelator, on T-cell function.
    Bierer BE; Nathan DG
    Blood; 1990 Nov; 76(10):2052-9. PubMed ID: 2242426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extracellular iron chelators protect kidney cells from hypoxia/reoxygenation.
    Paller MS; Hedlund BE
    Free Radic Biol Med; 1994 Dec; 17(6):597-603. PubMed ID: 7532608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
    Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
    J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphocyte activation, iron uptake and release by human mononuclear leukocytes in the presence of desferrioxamine.
    Taylor PG; Soyano A; Romano E; Layrisse M
    Immunopharmacol Immunotoxicol; 1988; 10(2):165-78. PubMed ID: 3171105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.